knowledge -WSS

knowledge

author：knowledge 2025-09-03 09:25:21 - browse：3357

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： CVS is on a mission to consolidate health care. Will it work?

hotspot

WSS

Maisha Meds is a PBM, but don't call it that

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Ionis has late

FDA endorses new sterilization method for medical devices

Shingles, which affected Dianne Feinstein, is on the rise

Paxlovid should be available without a positive Covid test

focus

knowledge

hotspot

Sports medicine is finally prioritizing gender equality

Head of FDA's diagnostics center, who led through Covid, retires

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

HPV vaccine, cervical cancer study delivers historic results

Hollywood unions extend contract negotiations for actors

Covid vaccines: Private market messier than government rollout

Wildfire smoke exposes gaps in outdoor worker protections

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Peter Hotez and the public health issue of online harassment

Mass General, Mayo Clinic look to monetize custom

entertainment

FDA endorses new sterilization method for medical devices

Medicare bonuses could stop drug shortages under Senate plan

Ionis has late

FDA endorses new sterilization method for medical devices

Medicaid, Medicare dual

How one patient went off dialysis — and others can too

hotspot

hotspot

focus

leisure time